Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Dr. Arevitalize vs Willow

Dr. Arevitalize
Site position #250

Higher grade

Willow
Site position #342

Lower grade

The verdict

Dr. Arevitalize takes it — 65.2/100 to 58.2/100.

Dr. Arevitalize grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Dr. Arevitalize (Dr.Arevitalize Health, Inc.) is a LegitScript-certified telehealth platform offering compounded GLP-1 weight-loss medication in both injectable and oral-capsule forms — semaglutide from $269/mo and tirzepatide from $349/mo, sold in 1-, 3-, 6-, and 12-month bundles.

We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueDr. Arevitalize +3
39
36
Dose & formulationEven
75
75
Clinical oversightEven
71
71
Labs & monitoringDr. Arevitalize +36
88
52
FulfillmentDr. Arevitalize +7
72
65
Contract termsEven
55
55
Dr. Arevitalize · top barWillow · bottom bar

The numbers

MetricDr. ArevitalizeWillow
WeighScore65.2/10058.2/100
GradeCC
Site position#250#342
Semaglutide$319/mo (compounded)$299/mo (starting dose, compounded)
Tirzepatide$359/mo (compounded)$399/mo (starting dose, compounded)
CoverageCoverage not publishedCoverage not published
Brand-name accessNot confirmedNot confirmed
Oral / sublingualYesYes
Dr. Arevitalize

Site position #250 · C

Strengths

  • Offers both injectable and oral-capsule compounded GLP-1 — a needle-free option many providers do not carry
  • Semaglutide from $269/mo and tirzepatide from $349/mo, in 1-, 3-, 6-, and 12-month bundles
  • LegitScript-certified; clinician-guided with lab/bloodwork analysis and personalized plans
  • Intro pricing on injectable semaglutide ($269, was $319) and oral semaglutide ($299, was $349)

Where it loses points

  • Compounded GLP-1s are not FDA-approved finished products
  • Compounding pharmacy partner and prescribing clinician are not named on the site
  • State availability is not published on the site
Willow

Site position #342 · C

Strengths

  • Both semaglutide and tirzepatide available
  • Compounded GLP-1 access

Where it loses points

  • Limited public information on program details

Featured provider

Willow

Willow scores 58.2/100 (C). Telehealth provider offering compounded GLP-1 medications in both tablet and injectable formats.

Commercial relationships affect this placement. The score comparison above is separate.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard